Analysts Revise 10x Genomics Price Targets After Q3 Earnings
Deutsche Bank cut its target to $50 from $70 and kept a Hold rating; UBS cut its target to $61 from $90 and maintained Neutral. Stifel raised its target to $68 from $50 and maintained Buy.
Following 10x Genomics' third-quarter 2026 earnings report, several financial firms adjusted their outlooks on the company's stock. Deutsche Bank lowered its price target to $50 from $70 while maintaining a Hold rating. UBS also reduced its price target, moving it to $61 from $90, and maintained a Neutral rating. Conversely, Stifel maintained a Buy rating on the stock and increased its price target to $68 from $50.
These adjustments reflect analyst reactions to the company's recent financial performance and updated 2026 guidance.